Vigencell’s Life-Saving New Drug Candidate Showcases Promising Results
Money Today reporter Kim Do-yoon | 25.01.2024 16:36 Vigencell is currently conducting Phase 2 clinical trials of its lead immuno-oncology drug and is accelerating to commercialization next year. Expectations are high as this is a new drug candidate that has achieved a 100% overall survival rate in real-world patient studies. In addition, the development of […]
